遺伝子ベクター市場(ベクタータイプ:レンチウイルス、アデノウイルス、アデノ随伴ウイルス(AAV)、プラスミドDNA、その他、疾患:遺伝性疾患、がん、感染症、その他)-世界の産業分析、サイズ、シェア、成長、トレンド、および予測、2022-2031年Gene Vector Market (Vector Type: Lentivirus, Adenovirus, Adeno-associated Virus (AAV), Plasmid DNA, and Others, Disease: Genetic Disorder, Cancer, Infectious Disease, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 遺伝子ベクター市場 - レポートの範囲 TMRの調査レポート「遺伝子ベクターの世界市場」は、2022年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と... もっと見る
サマリー遺伝子ベクター市場 - レポートの範囲TMRの調査レポート「遺伝子ベクターの世界市場」は、2022年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2022年を基準年、2031年を予測年として、2017年から2031年の期間における世界の遺伝子ベクター市場の収益を提供します。また、2022年から2031年までの世界の遺伝子ベクター市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行った。二次調査では、遺伝子ベクター市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照しました。 二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、世界の遺伝子ベクター市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチを組み合わせて採用しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の遺伝子ベクター市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の遺伝子ベクター市場への参入を検討している企業にとっても貴重なツールになります。 本レポートでは、世界の遺伝子ベクター市場の競争環境について掘り下げています。世界の遺伝子ベクター市場で活動する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の遺伝子ベクター市場のプレイヤーの属性です。 研究方法論 調査方法は、徹底的な一次調査と二次調査を組み合わせて、市場の遺伝子ベクターを分析する予定です。 二次調査 二次調査には、企業の文献、技術文書、特許データ、インターネット上の情報源、政府ウェブサイト、業界団体、機関などの統計データなどの検索が含まれます。これは、正確なデータを入手し、業界関係者の洞察を得て、ビジネスチャンスを認識するための最も信頼性が高く、効果的で成功した方法であることが証明されています。 一般的に参照する二次研究資料は、これらに限定されるものではありません: 企業ウェブサイト、プレゼンテーション、アニュアルレポート、ホワイトペーパー、テクニカルペーパー、製品パンフレット 社内外の独自データベースや関連特許の紹介 各国政府資料、統計データベース、マーケットレポートなど 市場に参入している企業に特化したニュース記事、プレスリリース、ウェブキャストを配信しています。 具体的な二次資料 - 業界の情報源 o WorldWideScience.org o Elsevier, Inc. o 米国国立衛生研究所(NIH) o PubMed o NCBI o ヘルスケアサービス部門 - 貿易データソース o トレードマップ o 国連コムトレード o トレードアトラス - 会社情報 o OneSource Business Browser オ・フーバーズ o ファクティバ O ブルームバーグ - M&A(合併・買収 o トムソンM&Aについて o MergerStat o プロファウンド 一次調査 調査期間中、幅広い業界関係者やオピニオンリーダーとの綿密なインタビューやディスカッションを実施しました。調査の大部分は一次調査であり、二次調査によって補完されています。 データおよび分析の検証のため、業界関係者やコメンテーターへの一次インタビューを継続的に実施しています。典型的なリサーチ・インタビューは、以下のような機能を果たしています: 市場規模、市場動向、成長トレンド、競争環境、展望などに関する生の情報を提供します。 二次調査結果の検証や強化に役立つ 分析チームの専門知識と市場理解のさらなる発展 地域ごとの市場、カテゴリー、セグメント、サブセグメントについて、電子メールでのやりとり、電話取材、対面取材を含むプライマリーリサーチを実施。 このようなプロセスに通常参加する参加者は、これらに限定されるものではありません: 業界関係者の方マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャー、リージョナルセールスマネージャー 購買・調達担当者、技術担当者、販売代理店 外部の専門家:投資銀行、バリュエーション専門家、特定市場を専門とするリサーチアナリストなど 各業界に対応した各分野の専門家であるキーオピニオンリーダー。 主な参加者のリスト(ただし、これらに限定されない): アドバンスト・オンコセラピーPLC Danfysik A/S 株式会社日立製作所 IBA ワールドワイド メビオンメディカルシステムズ株式会社 データの三角測量:二次資料・一次資料」から抽出された情報は、四半期ごとに更新される「TMR Knowledge Repository」と照合されます。 市場推定:市場規模の推定には、製品の特徴、技術の更新、地理的存在、製品の需要、販売データ(金額または数量)、過去の前年比成長率などの詳細な調査が含まれます。また、市場規模や予測を導き出すために、他のアプローチも活用した。ハードデータがない場合は、包括的なデータセットを作成するためにモデリング技法を採用した。厳密な方法論を採用し、入手可能なハードデータと以下のデータタイプを相互参照し、推定値を作成した: 人口動態データ:医療費支出、インフレ率、その他 産業指標研究開発投資、技術段階、インフラ、部門成長、設備など 市場予測:市場の促進要因、阻害要因/課題、機会を考慮し、他のセグメント/サブセグメントに対するメリット/デメリットを考慮した上で、様々なセグメントの市場予測を行います。ビジネス環境、過去の販売パターン、アンメットニーズ、競争力、国別の手術データなども、市場予測を導き出すために考慮される重要な要素のひとつです。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Gene Vector Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.1.2. Industry Evolution/Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Technological Advancements 5.2. Major Research Institutes Involved 5.3. Disease Prevalence & Incidence Rate globally with key countries 5.4. COVID-19 Pandemic Impact on Industry 6. Global Gene Vector Market Analysis and Forecast, by Vector Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Vector Type, 2017 - 2031 6.3.1. Lentivirus 6.3.2. Adenovirus 6.3.3. Adeno-associated Virus (AAV) 6.3.4. Plasmid DNA 6.3.5. Others 6.4. Market Attractiveness, by Vector Type 7. Global Gene Vector Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017 - 2031 7.3.1. Gene Therapy 7.3.2. Vaccinology 7.3.3. Others 7.4. Market Attractiveness, by Application 8. Global Gene Vector Market Analysis and Forecast, by Disease 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Disease, 2017 - 2031 8.3.1. Genetic Disorder 8.3.2. Cancer 8.3.3. Infectious Disease 8.3.4. Others 8.4. Market Attractiveness, by Disease 9. Global Gene Vector Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by End-user, 2017 - 2031 9.3.1. Scientific Research 9.3.2. CRO 9.3.3. CDMO 9.3.4. Others (Pharmaceutical, Biotechnology Companies) 9.4. Market Attractiveness, by End-user 10. Global Gene Vector Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness, by Country/Region 11. North America Gene Vector Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Vector Type, 2017 - 2031 11.2.1. Lentivirus 11.2.2. Adenovirus 11.2.3. Adeno-associated Virus (AAV) 11.2.4. Plasmid DNA 11.2.5. Others 11.3. Market Value Forecast, by Application, 2017 - 2031 11.3.1. Gene Therapy 11.3.2. Vaccinology 11.3.3. Others 11.4. Market Value Forecast, by Disease, 2017 - 2031 11.4.1. Genetic Disorder 11.4.2. Cancer 11.4.3. Infectious Disease 11.4.4. Others 11.5. Market Value Forecast, by End-user, 2017 - 2031 11.5.1. Scientific Research 11.5.2. CRO 11.5.3. CDMO 11.5.4. Others (Pharmaceutical, Biotechnology Companies) 11.6. Market Value Forecast, by Country, 2017 - 2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Vector Type 11.7.2. By Application 11.7.3. By Disease 11.7.4. By End-user 11.7.5. By Country 12. Europe Gene Vector Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Vector Type, 2017 - 2031 12.2.1. Lentivirus 12.2.2. Adenovirus 12.2.3. Adeno-associated Virus (AAV) 12.2.4. Plasmid DNA 12.2.5. Others 12.3. Market Value Forecast, by Application, 2017 - 2031 12.3.1. Gene Therapy 12.3.2. Vaccinology 12.3.3. Others 12.4. Market Value Forecast, by Disease, 2017 - 2031 12.4.1. Genetic Disorder 12.4.2. Cancer 12.4.3. Infectious Disease 12.4.4. Others 12.5. Market Value Forecast, by End-user, 2017 - 2031 12.5.1. Scientific Research 12.5.2. CRO 12.5.3. CDMO 12.5.4. Others (Pharmaceutical, Biotechnology Companies) 12.6. Market Value Forecast, by Country, 2017 - 2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Spain 12.6.5. Italy 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Vector Type 12.7.2. By Application 12.7.3. By Disease 12.7.4. By End-user 12.7.5. By Country 13. Asia Pacific Gene Vector Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Vector Type, 2017 - 2031 13.2.1. Lentivirus 13.2.2. Adenovirus 13.2.3. Adeno-associated Virus (AAV) 13.2.4. Plasmid DNA 13.2.5. Others 13.3. Market Value Forecast, by Application, 2017 - 2031 13.3.1. Gene Therapy 13.3.2. Vaccinology 13.3.3. Others 13.4. Market Value Forecast, by Disease, 2017 - 2031 13.4.1. Genetic Disorder 13.4.2. Cancer 13.4.3. Infectious Disease 13.4.4. Others 13.5. Market Value Forecast, by End-user, 2017 - 2031 13.5.1. Scientific Research 13.5.2. CRO 13.5.3. CDMO 13.5.4. Others (Pharmaceutical, Biotechnology Companies) 13.6. Market Value Forecast, by Country, 2017 - 2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Vector Type 13.7.2. By Application 13.7.3. By Disease 13.7.4. By End-user 13.7.5. By Country 14. Latin America Gene Vector Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Vector Type, 2017 - 2031 14.2.1. Lentivirus 14.2.2. Adenovirus 14.2.3. Adeno-associated Virus (AAV) 14.2.4. Plasmid DNA 14.2.5. Others 14.3. Market Value Forecast, by Application, 2017 - 2031 14.3.1. Gene Therapy 14.3.2. Vaccinology 14.3.3. Others 14.4. Market Value Forecast, by Disease, 2017 - 2031 14.4.1. Genetic Disorder 14.4.2. Cancer 14.4.3. Infectious Disease 14.4.4. Others 14.5. Market Value Forecast, by End-user, 2017 - 2031 14.5.1. Scientific Research 14.5.2. CRO 14.5.3. CDMO 14.5.4. Others (Pharmaceutical, Biotechnology Companies) 14.6. Market Value Forecast, by Country, 2017 - 2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Vector Type 14.7.2. By Application 14.7.3. By Disease 14.7.4. By End-user 14.7.5. By Country 15. Middle East & Africa Gene Vector Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Vector Type, 2017 - 2031 15.2.1. Lentivirus 15.2.2. Adenovirus 15.2.3. Adeno-associated Virus (AAV) 15.2.4. Plasmid DNA 15.2.5. Others 15.3. Market Value Forecast, by Application, 2017 - 2031 15.3.1. Gene Therapy 15.3.2. Vaccinology 15.3.3. Others 15.4. Market Value Forecast, by Disease, 2017 - 2031 15.4.1. Genetic Disorder 15.4.2. Cancer 15.4.3. Infectious Disease 15.4.4. Others 15.5. Market Value Forecast, by End-user, 2017 - 2031 15.5.1. Scientific Research 15.5.2. CRO 15.5.3. CDMO 15.5.4. Others (Pharmaceutical, Biotechnology Companies) 15.6. Market Value Forecast, by Country, 2017 - 2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Vector Type 15.7.2. By Application 15.7.3. By Disease 15.7.4. By End-user 15.7.5. By Country 16. Competition Landscape 16.1. Market Player – Competition Matrix (By Tier and Size of companies) 16.2. Market Share Analysis By Company (2021) 16.3. Company Profiles 16.3.1. Lonza 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Merck KGaA 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Oxford Biomedica 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. CGT Catapult 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Charles River Laboratories 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. uniQure N.V. 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. FUJIFILM Diosynth Biotechnologies 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Spark Therapeutics, Inc. 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Other Prominent Players 図表リストList of TablesTable 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
SummaryGene Vector Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Gene Vector Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.1.2. Industry Evolution/Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Technological Advancements 5.2. Major Research Institutes Involved 5.3. Disease Prevalence & Incidence Rate globally with key countries 5.4. COVID-19 Pandemic Impact on Industry 6. Global Gene Vector Market Analysis and Forecast, by Vector Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Vector Type, 2017 - 2031 6.3.1. Lentivirus 6.3.2. Adenovirus 6.3.3. Adeno-associated Virus (AAV) 6.3.4. Plasmid DNA 6.3.5. Others 6.4. Market Attractiveness, by Vector Type 7. Global Gene Vector Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017 - 2031 7.3.1. Gene Therapy 7.3.2. Vaccinology 7.3.3. Others 7.4. Market Attractiveness, by Application 8. Global Gene Vector Market Analysis and Forecast, by Disease 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Disease, 2017 - 2031 8.3.1. Genetic Disorder 8.3.2. Cancer 8.3.3. Infectious Disease 8.3.4. Others 8.4. Market Attractiveness, by Disease 9. Global Gene Vector Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by End-user, 2017 - 2031 9.3.1. Scientific Research 9.3.2. CRO 9.3.3. CDMO 9.3.4. Others (Pharmaceutical, Biotechnology Companies) 9.4. Market Attractiveness, by End-user 10. Global Gene Vector Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness, by Country/Region 11. North America Gene Vector Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Vector Type, 2017 - 2031 11.2.1. Lentivirus 11.2.2. Adenovirus 11.2.3. Adeno-associated Virus (AAV) 11.2.4. Plasmid DNA 11.2.5. Others 11.3. Market Value Forecast, by Application, 2017 - 2031 11.3.1. Gene Therapy 11.3.2. Vaccinology 11.3.3. Others 11.4. Market Value Forecast, by Disease, 2017 - 2031 11.4.1. Genetic Disorder 11.4.2. Cancer 11.4.3. Infectious Disease 11.4.4. Others 11.5. Market Value Forecast, by End-user, 2017 - 2031 11.5.1. Scientific Research 11.5.2. CRO 11.5.3. CDMO 11.5.4. Others (Pharmaceutical, Biotechnology Companies) 11.6. Market Value Forecast, by Country, 2017 - 2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Vector Type 11.7.2. By Application 11.7.3. By Disease 11.7.4. By End-user 11.7.5. By Country 12. Europe Gene Vector Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Vector Type, 2017 - 2031 12.2.1. Lentivirus 12.2.2. Adenovirus 12.2.3. Adeno-associated Virus (AAV) 12.2.4. Plasmid DNA 12.2.5. Others 12.3. Market Value Forecast, by Application, 2017 - 2031 12.3.1. Gene Therapy 12.3.2. Vaccinology 12.3.3. Others 12.4. Market Value Forecast, by Disease, 2017 - 2031 12.4.1. Genetic Disorder 12.4.2. Cancer 12.4.3. Infectious Disease 12.4.4. Others 12.5. Market Value Forecast, by End-user, 2017 - 2031 12.5.1. Scientific Research 12.5.2. CRO 12.5.3. CDMO 12.5.4. Others (Pharmaceutical, Biotechnology Companies) 12.6. Market Value Forecast, by Country, 2017 - 2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Spain 12.6.5. Italy 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Vector Type 12.7.2. By Application 12.7.3. By Disease 12.7.4. By End-user 12.7.5. By Country 13. Asia Pacific Gene Vector Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Vector Type, 2017 - 2031 13.2.1. Lentivirus 13.2.2. Adenovirus 13.2.3. Adeno-associated Virus (AAV) 13.2.4. Plasmid DNA 13.2.5. Others 13.3. Market Value Forecast, by Application, 2017 - 2031 13.3.1. Gene Therapy 13.3.2. Vaccinology 13.3.3. Others 13.4. Market Value Forecast, by Disease, 2017 - 2031 13.4.1. Genetic Disorder 13.4.2. Cancer 13.4.3. Infectious Disease 13.4.4. Others 13.5. Market Value Forecast, by End-user, 2017 - 2031 13.5.1. Scientific Research 13.5.2. CRO 13.5.3. CDMO 13.5.4. Others (Pharmaceutical, Biotechnology Companies) 13.6. Market Value Forecast, by Country, 2017 - 2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Vector Type 13.7.2. By Application 13.7.3. By Disease 13.7.4. By End-user 13.7.5. By Country 14. Latin America Gene Vector Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Vector Type, 2017 - 2031 14.2.1. Lentivirus 14.2.2. Adenovirus 14.2.3. Adeno-associated Virus (AAV) 14.2.4. Plasmid DNA 14.2.5. Others 14.3. Market Value Forecast, by Application, 2017 - 2031 14.3.1. Gene Therapy 14.3.2. Vaccinology 14.3.3. Others 14.4. Market Value Forecast, by Disease, 2017 - 2031 14.4.1. Genetic Disorder 14.4.2. Cancer 14.4.3. Infectious Disease 14.4.4. Others 14.5. Market Value Forecast, by End-user, 2017 - 2031 14.5.1. Scientific Research 14.5.2. CRO 14.5.3. CDMO 14.5.4. Others (Pharmaceutical, Biotechnology Companies) 14.6. Market Value Forecast, by Country, 2017 - 2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Vector Type 14.7.2. By Application 14.7.3. By Disease 14.7.4. By End-user 14.7.5. By Country 15. Middle East & Africa Gene Vector Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Vector Type, 2017 - 2031 15.2.1. Lentivirus 15.2.2. Adenovirus 15.2.3. Adeno-associated Virus (AAV) 15.2.4. Plasmid DNA 15.2.5. Others 15.3. Market Value Forecast, by Application, 2017 - 2031 15.3.1. Gene Therapy 15.3.2. Vaccinology 15.3.3. Others 15.4. Market Value Forecast, by Disease, 2017 - 2031 15.4.1. Genetic Disorder 15.4.2. Cancer 15.4.3. Infectious Disease 15.4.4. Others 15.5. Market Value Forecast, by End-user, 2017 - 2031 15.5.1. Scientific Research 15.5.2. CRO 15.5.3. CDMO 15.5.4. Others (Pharmaceutical, Biotechnology Companies) 15.6. Market Value Forecast, by Country, 2017 - 2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Vector Type 15.7.2. By Application 15.7.3. By Disease 15.7.4. By End-user 15.7.5. By Country 16. Competition Landscape 16.1. Market Player – Competition Matrix (By Tier and Size of companies) 16.2. Market Share Analysis By Company (2021) 16.3. Company Profiles 16.3.1. Lonza 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Merck KGaA 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Oxford Biomedica 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. CGT Catapult 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Charles River Laboratories 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. uniQure N.V. 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. FUJIFILM Diosynth Biotechnologies 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Spark Therapeutics, Inc. 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Other Prominent Players List of Tables/GraphsList of TablesTable 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017–2031 Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031 Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031 Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
Transparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(dna)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/09 10:27 143.78 円 159.73 円 191.51 円 |